Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Brolucizumab, also known as RTH258 or ESBA1008, 4 is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019. 6.
ESBA1008; ESBA-1008; RTH258
100 µg
Searching for an antibody we don't offer? We make custom antibodies for specific targets, species and applications.
More than 18,000 custom antibodies created so far.
Talk to a specialist nowIf an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn moreGet expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support